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Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a polyglutamine expansion in the hunting-
tin protein (htt). Increasing evidence suggests that transglutaminase (TGase) plays a critical role in the pathophysiology of HD possibly
by stabilizing monomeric, polymeric and aggregated htt. We previously reported that in HEK293 and SH-SY5Y cells expression of a
calmodulin (CaM)-fragment, consisting of amino acids 76-121 of CaM, decreased binding of CaM to mutant htt, TGase-modified htt and
cytotoxicity associated with mutant htt and normalized intracellular calcium release. In this study, an adeno-associated virus (AAV) that
expresses the CaM-fragment was injected into the striatum of HD transgenic R6/2 mice. The CaM-fragment significantly reduced body
weight loss and improved motor function as indicated by improved rotarod performance, longer stride length, lower stride frequency,
fewer low mobility bouts and longer travel distance than HD controls. A small but insignificant increase in survival was observed in R6/2
mice with CaM-fragment expression. Immunoprecipitation studies show that expression of the CaM-fragment reduced TGase-modified
htt in the striatum of R6/2 mice. The percentage of htt-positive nuclei and the size of intranuclear htt aggregates were reduced by the
CaM-fragment without striatal volume changes. The effects of CaM-fragment appear to be selective, as activity of another CaM-dependent
enzyme, CaM-dependent kinase II, was not altered. Moreover, inhibition of TGase-modified htt was substrate-specific since overall TGase
activity in the striatum was not altered by treatment with the CaM-fragment. Together, these results suggest that disrupting CaM– htt
interaction may provide a new therapeutic strategy for HD.
Introduction
Patients with Huntington’s disease (HD) present symptoms such
as chorea, irregular gait, reduced motor coordination and weight
loss (Harper, 1991). HD is a progressive and fatal neurological
disorder caused by expansion of CAG repeats in HTT gene, con-
ferring a toxic gain of function to the huntingtin (htt) protein
(Huntington’s Disease Collaborative Research Group, 1993). It is
characterized neuropathologically by intranuclear inclusions and
cytoplasmic aggregates composed of htt with an expanded poly-
glutamine domain (DiFiglia et al., 1997; Ross et al., 1998). Cur-
rently, there are no effective treatments to prevent or slow the
progression of the disease.
Increasing evidence indicates that transglutaminases (TGases)
may contribute to the pathophysiology of HD (Cooper et al.,
1999; Karpuj et al., 2002a). TGases, a family of Ca 2-dependent
enzymes, catalyze a covalent bond between peptide-bound glu-
tamine residues and either lysine-bound peptide residues or
mono- or polyamines (Folk et al., 1980; Griffin et al., 2002). In cell
culture, mutant htt is an excellent substrate for TGases (Gentile et
al., 1998; Kahlem et al., 1998; Zainelli et al., 2005). The mRNA,
protein and enzymatic activity of TGases are elevated in HD brain
(Karpuj et al., 1999; Lesort et al., 1999; Zainelli et al., 2003). TGase
2 ablation in HD transgenic mice resulted in a drastic reduction
in (-glutamyl) lysine bond levels and neuronal death in the
cortex and striatum (Mastroberardino et al., 2002). Administra-
tion of the TGase inhibitor, cystamine, extended survival and
improved motor performance in HD transgenic mice (Karpuj et
al., 2002b).
Calmodulin (CaM) increased TGase activity in human eryth-
rocyte (Billett and Puszkin, 1991), platelets and chicken gizzard
(Puszkin and Raghuraman, 1985). CaM activates a host of en-
zymes upon Ca 2 binding (Cheung, 1982) and associates with
mutant htt as demonstrated by affinity purification (Bao et al.,
1996) and immunoprecipitation (Zainelli et al., 2004). More-
over, CaM colocalizes with htt and TGase 2 in HD intranuclear
inclusions (Zainelli et al., 2004). Since a CaM inhibitor decreased
TGase-catalyzed cross-linking of htt in cells (Zainelli et al., 2004),
we tested the ability of fragments of CaM to interrupt the
interaction of CaM and mutant htt and decrease the deleteri-
ous effects of TGase in HEK-293 cells (Dudek et al., 2008). A
CaM-fragment, containing amino acids 76 –121, reduced
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binding of CaM to mutant htt in vitro and in HEK-293 cells.
Adeno-associated virus (AAV)-mediated expression of the
CaM-fragment significantly decreased TGase-modified htt,
and mutant htt-associated cytotoxicity in differentiated SH-
SY5Y cells, a neuroblastoma cell line, which stably express
mutant htt. Importantly, CaM-fragment did not alter the total
activity of TGase or another CaM-dependent enzyme, CaM ki-
nase II, suggesting that CaM-fragment has specific effects on the
CaM– htt interaction (Dudek et al., 2009). In the present study,
we assessed the therapeutic potential of CaM-fragment in the
R6/2 mouse model of HD. R6/2 transgenic mice express exon 1 of
the human HD gene with an increased CAG repeat. Conse-
quently, they develop a progressive neurological phenotype and
pathological changes that resemble many features of HD (Mang-
iarini et al., 1996; Li et al., 2000). Survival, body weight, motor
performance and neuropathological features were monitored to
determine whether AAV-mediated expression of the CaM-
fragment has beneficial effects on the course of HD in R6/2
mouse model.
Materials and Methods
Animals
Male R6/2 transgenic mice (with 100 –115 CAG repeats in the transgene)
and wild-type littermate mice were purchased from Jackson Laboratories
at 6 weeks of age. A reduction in the number of CAG repeats from the
original 154 –159 to 100 –115 was found in 2006, along with a delay in
the age of onset and a decrease in the severity of the neurological pheno-
type (Jackson Laboratories, http://jaxmice.jax.org/strain/002810.html).
The delayed onset of the neurological phenotype suggests that treatment
at 7 weeks of age should be sufficient to determine the treatment effect.
The mice had free access to food and water in an environment controlled
for temperature and humidity and a 12 h light/dark cycle. The behavioral
tests were conducted in the light part of the cycle. All procedures were
conducted in accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals as approved by the University of
Kansas Institutional Animal Care and Use Committee.
AAV injections
Recombinant AAV serotype 2 vectors were generated as described in our
previous studies (Dudek et al., 2009). Three resultant vectors expressed
each of the following: GFP and the CaM-fragment (containing amino
acids 76-121 of calmodulin), GFP and a scrambled peptide (containing
the same amino acids of the CaM-fragment but in a randomly scrambled
sequence), and GFP alone. The titers of final AAV products ranged from
2 to 5  10 14 vector genomes per ml. Bilateral striatal injections of
GFP-expressing AAV were performed in 7-week-old mice [1 l per side
with 200 nl/min infusion rate at coordinates of anterior/posterior 0.5
mm, lateral/medial 2 mm and dorsal/ventral 3 mm relative to
bregma (Franklin and Paxinos, 1997)]. Mice were randomly divided into
five groups (11–14 mice for each group) with a defined genotype and
treatment: CaM-HD (R6/2 mice injected with AAV expressing the CaM-
fragment), Vec-HD (R6/2 mice injected with empty vector AAV express-
ing GFP alone), Scr-HD (R6/2 mice injected with AAV expressing a
scrambled version of the CaM-fragment), CaM-WT (wild-type mice in-
jected with AAV expressing CaM-fragment) and Vec-WT (wild-type
mice injected with empty vector AAV).
Body weight and survival
Body weights were measured twice a week. Survival was checked twice
daily at 8 h intervals. Brains were removed after death and snap frozen in
2-methylbutane/dry ice bath and stored at 80°C.
Behavioral tests
Three behavioral tests were performed between 10 and 14 weeks of age at
weekly intervals. Gait dynamics, locomotion, and rotarod performance
were examined every Friday, Sunday, and Wednesday, respectively.
Gait dynamics. The DigiGait imaging system (Mouse Specifics) was
used for gait analyses as previously described (Hampton et al., 2004).
Briefly, mice were placed on a motorized transparent treadmill belt mov-
ing at a speed of 14 cm/s. Digital images of paw placement were recorded
at 150 Hz through a video camera mounted below the animal. The pro-
prietary software analyzed the resulting digital images to generate a set of
periodic waveforms that described the paw area and movement of each
limb relative to the treadmill belt through consecutive strides. Gait data
were pooled from all four paws and used to determine numerous gait
dynamic measures including stride length and frequency, variability of
stance width and paw area at peak stance.
Locomotion. To accurately measure locomotor behaviors including the
total distance traveled and the number of low mobility bouts (defined as
remaining continuously in a virtual circle of 15 mm radius for 10 s), a
force-plate actometer (constructed in Dr. Fowler’s laboratory, University
of Kansas) was used as described previously (Fowler et al., 2001). Mice
were placed in a 28 cm  28 cm force-plate actometer for a 30-min
recording once a week. When the animal moves on the plate, its move-
ments are sensed by four supporting force transducers positioned at the
corners of the plate. The signals are processed by specialized computer
algorithms written in house to yield measurements of travel distance and
bouts of low mobility.
Rotarod performance. A rotarod apparatus (MED-Associates) was used
to measure fore- and hindlimb motor coordination and balance. The
mice were given a training session at 9 weeks of age (four trials per day for
3 consecutive days) to acclimate them to the rotarod apparatus. During
the test period, each mouse was placed on the rotarod with increasing
speed, from 4 rpm to 40 rpm in 300 s. The latency to fall off the rotarod
within this time period was recorded. Mice were tested on the rotarod
once a week. Each mouse received two consecutive trials and the mean
latency to fall was used in the analysis.
Immunoprecipitation
Mouse brains were bisected mid-sagittally. One half was used in immu-
noprecipitation (IP), CaM kinase II activity, and TGase assays. The other
half was used for immunohistochemistry assays. To prepare striatal ho-
mogenates for IP, a half brain was cut into 300 m coronal sections with
a cryostat (Leica). Striatum was punched out from five consecutive sec-
tions and homogenized in lysate buffer (10 mM Tris-HCl, pH 7.5, 0.14 M
NaCl, 1 mM EDTA, and 1:1000 protease inhibitor mixture) in a Tissue
Tek homogenizer. Protein concentration was determined using the BCA
Protein Assay kit (Pierce Chemical) and tissue homogenates containing
150 g of protein were centrifuge at 12,000  g for 5 min at 4°C to
separate the insoluble fraction. After removal of the supernatant, the
insoluble fraction was resuspended in 60 l of 95% formic acid and
incubated in a shaking water bath at 37°C for 40 min. The formic acid was
then evaporated using a CentriVap Speed Vacuum (Labconco) for 1.5 h
at 45°C. The pellets were resuspended in 150 l of IP wash buffer (10 mM
Tris-HCl, pH 7.5, 0.14 M NaCl, and 0.1% Tween 20) and sonicated on ice
at 10  5 s pulse. Immunopurification of proteins containing TGase-
catalyzed bonds was performed using 81D4 monoclonal antibody pre-
bound to Sepharose beads (CovalAb) using a protocol developed by
CovalAb and as described previously (Norlund et al., 1999; Zainelli et al.,
2005).
Immunoblot
Immunoaffinity-purified proteins were separated on 10% SDS-polyacrylamide
gels and then electrophoretically transferred to nitrocellulose mem-
branes. Membranes were then incubated in blocking buffer (5% nonfat
dry milk, 0.1% Tween 20, and 1 TBS) for 1 h at room temperature.
Membranes were incubated overnight at 4°C with primary antibody on a
shaker. Primary antibody (Millipore Bioscience Research Reagents: anti-
Huntingtin aa 1-82, mouse IgG, 1:500) was diluted in antibody buffer
(1% nonfat dry milk, 0.1% Tween 20, and 1 TBS). The next day, mem-
branes were washed with TBS/0.1% Tween 20, and then they were incubated
with goat anti-mouse secondary antibody conjugated to horseradish perox-
idase (Jackson ImmunoResearch Laboratories) diluted in antibody
buffer. Membranes were washed, and signal was detected using enhanced
chemiluminescence Western blotting detection reagents (GE Health-
care). Using Scion Image for Windows, immunoblots were quantified by
calculating the integrated optical density (IOD) of each protein band on
the film.
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Evaluation of htt aggregates by immunofluorescence
Sections of frozen mouse brain tissue (20 m thick) were mounted on
glass slides, and then fixed in 4% paraformaldehyde. After fixation, the
sections were washed in PBS, pH 7.4, and then nonspecific binding was
blocked with 5% normal goat serum (NGS). Sections were incubated
overnight with primary antibody: MAB5374 (mouse IgG, 1:100, directed
against human huntingtin amino acids 1–256) in 1% NGS  1 PBS.
Next, sections were washed and incubated for 1 h with secondary anti-
body: goat anti-mouse IgG, Fc fragment specific, conjugated to DyLight
649 (1:400) (Jackson ImmunoResearch). Next, coverslips were mounted
on tissue sections with Prolong Gold antifade reagent with DAPI (In-
vitrogen). As a control for nonspecific labeling with secondary antibody,
omission of the primary antibody was also performed on a slide from
each case. Htt-aggregate positive nuclei and size of htt-aggregates were
measured in each of ten 215 215 m microscope fields by Olympus
IX-81 microscope, in each of five rostrocaudally spaced sections in the
striatum of 5 mice from the three groups of R6/2 mice (wild-type litter-
mates did not show htt immunoreactivity). At least 450 nuclei per mouse
were obtained and the percentage of nuclei containing htt-aggregates and
area of htt-aggregates were calculated by CellProfiler software (White-
head Institute for Biomedical Research, Cambridge, MA) and a mean
value was obtained for each group.
Measurement of striatal volume by Nissl staining
Cryostat sections (20 m thick) were postfixed in 4% paraformaldehyde,
then dehydrated in graded alcohols. After being delipidated in 1:1 alco-
hol/chloroform for 1.5 h, sections were rehydrated through graded alco-
hols and stained with 0.2% aqueous solution of cresyl violet (Sigma) for
5 min, followed by a brief rinse with water and dehydration in graded
alcohols. Sections were cleared in xylene (two changes, 5 min each) and
coverslipped with Permount (Fisher Scientific). The volume of the stri-
atum was measured according to the principle of Cavalieri (Cyr et al.,
2005) (volume  s1d1  s2d2…sndn, where s  surface area and d 
distance between two sections). We considered 15 coronal levels of the
striatal sections (from bregma 1.7 mm, with an interval of 200 m be-
tween the sections) for the volumetric measurement study. Image cap-
turing was performed by using an inverted microscope (Olympus IX-81)
coupled to a digital camera (Hamamatsu EMCCD). The montage image
of a coronal brain section was constructed by Slidebook (Intelligent Im-
aging Innovations). The surface area of striatum in each section was
measured using NIH ImageJ (http://rsbweb.nih.gov/ij/). Data were ex-
pressed as the average Cavalieri volume SEM (mm 3) of 4 –5 mice per
group.
CaM kinase II activity assay
CaM kinase II enzyme activity was analyzed using the SignaTECT
Calcium/Calmodulin-Dependent Protein Kinase Assay System (Pro-
mega), according to the manufacturer’s protocol. Mouse striatum was
homogenized in the extraction buffer [20 mM Tris-HCl, pH 8.0, 2 mM
EDTA, 2 mM EGTA, 2 mM DTT, 1 mM PMSF and 1:1000 Protease Inhib-
itor Cocktail (Sigma)]. The homogenate was centrifuged at 350  g for 5
min at 4°C and the supernatant was mixed with [- 32P]ATP (at 3000Ci/
mmol, 10mCi/ml), 50 M biotinylated CaM kinase II substrate, reaction
buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl2 and 0.5 mM
DTT, with or without control buffer containing 1 mM EGTA. After incu-
bation at 30°C for 2 min, the reaction was terminated by adding 7.5 M
guanidine hydrochloride and spotted to a streptavidin-impregnated
membrane. Membranes were washed and the retained radioactive sub-
strate of CaM kinase II was quantitated by liquid scintillation counting
(Beckman). Radioactive counts were used as an index of endogenous
CaM kinase II activity in the sample.
TGase II activity assay
TGase activity was measured by detecting the incorporation of a biotin-
ylated TGase amine substrate, 5-(biotinamido)pentylamine (Pierce) into
N,N-dimethylcasein (Calbiochem) as previously described (Dudek et
al., 2009). Ninety-six-well Immulon 4 HBX plates (Dynatech) were
coated with 100 l of N,N-dimethylcasein (20 mg/ml) in 0.05 M sodium
bicarbonate, and stored at 4°C overnight. After the unbound N,N-
dimethylcasein was discarded, the plate was washed with PBS and
blocked with nonfat dry milk (2% milk in PBS) for 1 h at 37°C, followed
by 3 washes with PBS. Striatum from the various mice were homogenized
in 0.1 M Tris-HCl pH 8.3, 1 mM EDTA, 1 mM PMSF, and Protease Inhib-
itor Cocktail. Striatal homogenates (15 g of protein/sample) were
added to the plate with 0.1 M Tris-HCl pH 8.5, 0.15 M NaCl, 5 mM DTT,
0.5 mM biotin-labeled pentylamine, and 5 mM CaCl2. The mixture was
incubated for 1 h at 37°C. The plate was washed with TBS and 0.001%
Tween followed by incubation with streptavidin conjugated to HRP
(Jackson ImmunoResearch) for 1 h at room temperature. After five
washes, 1  TMB substrate solution (eBioscience) was added and color
was allowed to develop for 3 min. Then the reaction was stopped with 3N
sulfuric acid and the absorbance was read at 450 nm. For GTP-inhibited
TGase enzymatic activity, the assay was performed in the presence of 500
M GTPS (Sigma-Aldrich). Negative controls were run in the absence
of pentylamine or dimethylcasein. Each assay also included a standard
curve of varying amounts of guinea pig TGase (Sigma). Each sample was
measured in triplicate. TGase activity was converted to a percentage con-
trol based on the mean value for the Vec-WT mice.
Statistics
All data are presented as mean  SEM and analyzed by one- or two-way
ANOVA with repeated measures. Post hoc tests were conducted using
Bonferroni’s multiple-comparison tests. There were one or two mice
dead after week 13 in each HD group, so the last observed value was used
for the subsequent missing values. Survival time was demonstrated by
Kaplan–Meier survival curves and analyzed by a log-rank test. GB-STAT
10.0 (Dynamic Microsystems) and GraphPad Prism 5.0 were used for all
statistical analyses. A probability level of p  0.05 was considered to be
statistically significant for all statistical tests.
Results
AAV-mediated delivery of CaM-fragment in R6/2 mice
attenuated body weight loss
Body weight was monitored from 7 weeks of age onwards. All
groups of mice were of similar initial body weight (22.9  0.3 g,
n  10 –14 mice in each group). Changes in body weight were
expressed as a percentage of body weight measured at 7 weeks of
age (Fig. 1a). Body weight in all groups slowly increased or re-
mained unchanged until week 10. Thereafter, mice in the two
wild-type (WT) groups continued gaining body weight. The
Vec-HD (R6/2 mice injected with empty vector AAV expressing
GFP alone) and Scr-HD mice (R6/2 mice injected with AAV
expressing a scrambled version of the CaM-fragment) had pro-
found weight loss over the duration of the observation period,
whereas CaM-HD mice maintained their body weight, or slightly
increased their body weight (Fig. 1a). One-way ANOVA (F(4,50) 
82.48; p  0.0001) followed by Bonferroni’s multiple-comparison
test indicated that mice in CaM-HD group had less change in
body weight than those in the Vec-HD group at 12–16 weeks of
age ( p  0.05), and there was no significant difference in body
weight change between Scr-HD and Vec-HD at each time point.
Similarly, body weight change in the CaM-WT was not signifi-
cantly different from the Vec-WT.
CaM-fragment expression did not significantly increase R6/2
mice survival
Although the first death took place on days 88, 78, and 67 and
mean survival time was 112, 102.9, and 99.7 d in CaM-HD, Vec-
HD, and Scr-HD mice, respectively, suggesting a small (10%)
increase in life span of CaM-HD mice, Kaplan–Meier survival
curves demonstrated no statistically significant effect of CaM-
fragment expression on the mortality in R6/2 mice (Fig. 1b). By
log-rank comparison, the three groups of HD mice did not sig-
nificantly differ from each other ( p 	 0.05). None of the mice in
WT groups died during the observation period (from 6 to 27
weeks of age).
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CaM-fragment expression increases stride length and lowers
stride frequency in R6/2 mice
Gait dynamics were characterized using the DigiGait Imaging
System. Generally, there is a clear difference between WT mice
and Vec-HD or Scr-HD mice starting from week 11 in all the
parameters measured, whereas the difference between WT mice
and CaM-HD mice is not significant in stride length and fre-
quency. At a speed of 14 cm/s, WT mice maintained a regular
alternating gait at a consistent stride length of 5.8  0.3 cm and
stride frequency of 2.5  0.1 steps/s, whereas Vec-HD and Scr-HD
mice walked at a gradually reduced stride length and higher stride
frequency. For stride length (Fig. 2a), the two-way ANOVA with
repeated measures indicated a significant main effect of group
(F(4,126)  35.77; p  0.0001) and week (F(3,126)  12.12; p 
0.0001). There was also a significant interaction between group
and week (F(12,126)  5.71; p  0.0001). The post hoc Bonferroni
test indicated that stride length of CaM-HD mice is indistin-
guishable from the two HD control groups at 10 weeks of age, but
CaM-HD mice displayed a longer stride length compared with
Vec-HD or Scr-HD mice at weeks 11–13. Stride length of
CaM-HD mice was not significantly shorter than WT mice until
week 13. For stride frequency (Fig. 2b), two-way ANOVA indi-
cated significant differences among groups (F(4,126)  11.99; p 
0.0001), but there is no significant effect of week (F(3,126)  0.202;
p  0.895) or interaction between group and week (F(12,126) 
1.368; p  0.190). The Bonferroni test indicated that CaM-HD
mice had a significantly lower stride frequency than Vec-HD at
weeks 11–13. Although Vec-HD and Scr-HD were statistically
indistinguishable at any time point, there was a statistically sig-
nificant difference between CaM-HD and Scr-HD at week 12.
There was no significant difference between CaM-HD and WT
mice in stride frequency. Analysis of some other gait dynamics
revealed differences between genotypes. For example, the mea-
sure of stance width variation between steps was greater (Fig. 2c)
and paw area at peak stance was smaller (Fig. 2d) in HD mice than
in WT mice, but the CaM-fragment had no beneficial effects on
these gait indices. For stance width variation, two-way ANOVA
followed by Bonferroni test indicated significant differences be-
tween HD and WT groups (F(4,126) 
13.61; p  0.0001), but no significant
differences among HD groups or WT
groups ( p 	 0.05). There is no significant
effect of week (F(3,126)  1.21; p  0.31)
although interaction between group and
week is significant (F(12,126)  1.97; p 
0.03). Similar results were obtained in the
analysis of paw area at peak stance (Group
factor: F(4,126) 10.42; p0.0001), whereas
week effect is significant (F(3,126)  13.68;
p  0.0001) and interaction between
group and week is not (F(12,126)  1.55;
p  0.11).
CaM-HD mice had fewer low mobility
bouts and longer travel distance than
Scr-HD or Vec-HD mice
Force-plate actometers were used to mea-
sure the locomotor activity of R6/2 and
WT mice. The number of low mobility
bouts (LMB, defined as remaining contin-
uously in a virtual circle of 15 mm radius
for 10 s) is presented in Figure 3a. Two-
way ANOVA with repeated measures in-
dicated a significant effect of group (F(4,144)  27.75, p  0.001)
and a significant effect of week (F(3,144)  3.179, p  0.05), but the
interaction between group and week was not significant. The
number of LMB gradually increased in HD mice without CaM-
fragment expression, whereas CaM-HD mice, similar to WT
mice, maintained LMB at a relatively lower level. At weeks 12 and
13, the Bonferroni post hoc test detected significantly fewer LMB
in CaM-HD mice compared with either Scr-HD or Vec-HD
mice. Total travel distance in a 30 min session provided another
Figure 1. Effect of CaM-fragment on body weight and survival. a, Changes in body weight
were expressed as a percentage of body weight measured at 7 weeks of age. One-way ANOVA
and Bonferroni’s test found that the change in body weight was significantly smaller in CaM-HD
than in Vec-HD ( p  0.05) starting from week 12, and there is no significant difference be-
tween Scr-HD and Vec-HD. *p  0.05 (CaM-HD vs Vec-HD). b, Kaplan–Meier survival curves
showed the first death was at day 88, 78, and 67 in CaM-HD, Vec-HD, and Scr-HD mice, respec-
tively. By log-rank comparison, three groups of HD mice did not differ from each other ( p 	
0.05) (n  9 –14 in each group).
Figure 2. Video-based gait analysis on the treadmill. Mice were placed on a treadmill belt moving at a speed of 14 cm/s. Gait
data were pooled from all four paws. CaM-HD exhibited a significantly greater stride length (a) and a lower stride frequency (b).
There is no significant difference between CaM-HD and Vec-HD or Scr-HD in stance width variability (c) and paw area at peak stance
(d). Two-way ANOVA with repeated measures followed by Bonferroni test. *p  0.05 (CaM-HD vs Vec-HD), #p  0.05 (CaM-HD vs
Scr-HD). n  6 –14 in each group.
Dai et al. • Protective Effects of CaM-Fragment in R6/2 Mice J. Neurosci., September 16, 2009 • 29(37):11550 –11559 • 11553
index of locomotor activity of HD mice (Fig. 3b). Two-way
ANOVA with repeated measures indicated a significant effect of
group (F(4,138)  3.40, p  0.02), but the effect of week (F(3,138) 
0.17, p  0.92) and interaction between group and week (F(12,138) 
1.12, p  0.35) were not significant. Consistent with reduced
LMB in HD mice treated with CaM-fragment, CaM-fragment
expression also increased the locomotor activity in HD mice as
indicated by a significantly greater travel distance in CaM-HD
mice than in either Scr-HD (at weeks 12–13) or Vec-HD mice (at
week 12). There was no significant difference between CaM-HD
and WT mice in distance traveled in 30 min.
CaM-fragment improved performance on the rotarod in
R6/2 mice
Rotarod was used to measure fore- and hindlimb motor coordi-
nation and balance starting at 10 weeks of age (i.e., 3 weeks after
the AAV injections). At 10 weeks of age, the two groups of WT
mice were able to stay on the rod during the 300 s time period
measured, whereas none of the three groups of HD mice could
finish the test without falling in 300 s. Even at this early time point
after injection of the AAV, the mean latency to fall was signifi-
cantly differed among the HD groups, 245.9  32.0, 150.2  29.5,
98.1  19.8 s in CaM-HD, Vec-HD, and Scr-HD mice, respec-
tively. After 10 weeks of age, there was a progressive decline in
performance of all HD mice, but the CaM-HD mice still achieved
better performance than the other two HD groups (Fig. 4). Using
analysis using two-way ANOVA with repeated measurements, we
found a significant main effect of group (F(4,188)  49.35, p 
0.0001), a significant main effect of week (F(4,188)  18.86, p 
0.0001) and a significant interaction between group and week
(F(16,188)  4.714, p  0.0001) on latency to fall off the rotarod.
Bonferroni post hoc test indicated that CaM-HD mice had longer
latency to fall compared with Scr-HD mice at 10 –14 weeks of age
and Vec-HD mice at 10 –11 weeks of age ( p  0.05).
CaM-fragment expression reduced TGase-modified htt in
R6/2 mice striatum
Cell culture studies indicated that AAV-mediated CaM-fragment
expression can significantly inhibit the formation of TGase-
modified htt (Dudek et al., 2009). Here we used striatal ho-
mogenates from HD or WT mice to detect TGase-catalyzed
cross-linking of htt. Immunopurification of proteins containing
-(-glutamyl) lysine bonds was performed using 81D4 mAb
prebound to Sepharose beads. TGase-modified htt was then de-
tected on immunoblots as shown in the Figure 5a. TGase-
modified htt was only detected in HD but not WT mice. One-way
ANOVA (F(2,15)  18.44, p  0.0001) followed by Bonferroni’s
comparison test found there was a significant reduction (by
approximate 50%) in TGase-modified htt in the striatum of
Figure 3. Expression of CaM-fragment enhanced the locomotor activity in R6/2 mice. Spon-
taneous locomotor activities of R6/2 and WT control mice were recorded in a force-plate actom-
eter apparatus for 30 min. a, CaM-HD mice displayed a significantly smaller number of low
mobility bouts than the two HD control groups at weeks 12–13. b, Distance traveled by CaM-HD
mice was significantly longer than Scr-HD at weeks 12–13 and Vec-HD at week 12. Two-way
ANOVA with repeated measures followed by Bonferroni test. *p  0.05 (CaM-HD vs Vec-HD),
#p  0.05 (CaM-HD vs Scr-HD). n  9 –14 in each group.
Figure 4. CaM-fragment expression delayed the onset of the rotarod defects in R6/2 mice.
Mice were placed on a rotating rod with increasing speed, from 4 rpm to 40 rpm in 300 s. The
latency to fall off the rotarod within this time period was recorded. Two-way ANOVA with
repeated measures followed by Bonferroni test found that CaM-HD mice had significantly
longer latency to fall than Scr-HD starting from week 10, and than Vec-HD at weeks 10 –11.
*p  0.05 (CaM-HD vs Vec-HD), #p  0.05 (CaM-HD vs Scr-HD). n  9 –14 in each group.
Figure 5. TGase-modified htt in R6/2 mice striatum was reduced by CaM-fragment expres-
sion. a, The insoluble fraction from mouse striatal homogenates was dissolved with formic acid.
Immunopurification (IP) of proteins containing -(-glutamyl) lysine bonds was performed
using 81D4 mAb prebound to Sepharose beads. Immunopurified proteins were then examined
on immunoblots (IB) using an antibody against htt. b, Quantitation of immunoblots. Data
shown are the mean IOD  SEM, and they are normalized to CaM-HD mice. *p  0.05 com-
pared with CaM-HD (n  5 in each group at 13–14 weeks of age).
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CaM-HD mice compared with Scr-HD or Vec-HD mice
(Fig. 5b).
CaM-fragment expression decreases the percentage of htt-
positive nuclei and the size of htt aggregates in the striatum of
R6/2 mice
Striatal intranuclear and neuropil inclusions containing mutant
htt are prominent neuropathological hallmarks of HD and may
play an important role in disease progression. In R6/2 mice, in-
tranuclear aggregates are much larger than neuropil aggregates
and amenable to quantification, so we examined the effect of
CaM-fragment on intranuclear htt aggregates in the striatum of
R6/2 mice. In CaM-HD mice, the percentage of htt-positive nu-
clei was lower and the size of intranuclear aggregates appeared
smaller than in the control virus-treated
HD mice (Fig. 6a). These observations
were confirmed by quantification of nu-
clear aggregates (Table 1). We found a sig-
nificant reduction in the percentage of
striatal nuclei containing htt-aggregates
(18%) and the nuclear aggregate size
(35%) in CaM-HD mice compared with
either Vec- or Scr-HD mice. GFP fluores-
cence was observed in coronal brain sec-
tions from AAV-injected mice, indicating
a widespread infection and expression of
CaM-fragment in the striatum (Fig. 6a).
Both human HD and R6/2 mouse brains
are characterized by atrophy of the stria-
tum. To exam whether the CaM-fragment
delivery decreases gross striatal atrophy,
we used Nissl staining and the Cavalieri
principle to estimate striatal volumes.
There was no statistically significant dif-
ference in mean striatal volumes between
CaM-HD and the two groups of control
HD mice. However, all three groups of
HD mice had significantly smaller striatal
volumes compared with WT littermates
(Fig. 6b, Table 1). As expected, striatal
neuronal atrophy was observed in HD
mice in high-power images.
CaM kinase II activity was not affected
by CaM-fragment expression
To test whether expression of the CaM-
fragment would interfere with other
CaM-dependent enzymes, we measured
the activity of calmodulin-dependent pro-
tein kinase II (CaM kinase II) in mouse stri-
atal homogenates. We found no significant
differences in CaM kinase II activity among
the various HD or WT mouse groups in ei-
ther the presence or absence of EGTA, a cal-
cium chelator (Fig. 7a). However, EGTA
caused a general decrease in CaM kinase II
activity in all mouse groups. Two-way
ANOVA indicated a significant main effect
of EGTA (F(1,50)  72.12; p  0.0001), but
there was no significant effect of mouse
group (F(4,50)  0.543; p  0.705) or an
interaction between EGTA and group
(F(4,50)  0.966; p  0.435).
CaM-fragment did not change total TGase activity
To explore whether the reduced TGase-modified htt in CaM-HD
mice is due to a substrate-dependent inhibition or a general de-
crease in TGase enzymatic activity, we compared total TGase
activity in the striatum among the different groups of mice. There
is a significant increase in TGase activity in the three groups of
HD mice compared with CaM-WT or Vec-WT mice ( p  0.01).
Expression of the CaM-fragment did not have an effect on TGase
activity in either HD or WT mice. In the presence of GTPS,
which specifically inhibits TGase activity, TGase activity is dra-
matically reduced (at least 60%) in all groups (Fig. 7b). Two-way
ANOVA indicated a significant main effect of GTPS (F(1,50) 
428.149; p  0.0001) and mouse group (F(4,50)  5.535; p 
Figure 6. Histological evaluation of neuropathology. a, Top and middle, Immunofluorescent labeling of striatum in R6/2 mice
at 14 weeks of age. Htt-aggregates were labeled with htt antibody MAB5374 (red), the nuclei were labeled with DAPI (blue). The
composite images show that the percentage of htt-positive nuclei and the size of nuclear htt-aggregates were decreased in
CaM-HD compared with the control-HD mice. Scale bar, 30 m. Bottom, Photomicrographs of GFP distribution in the brain of
representative AAV-injected animals indicated that the same vector-derived CaM-fragment was expressed in the striatum. Scale
bar, 1 mm. b, Top, Montage images of Nissl-stained brain coronal sections from CaM-HD, Vec-HD, and CaM-WT mice at the level at
which the corpus callosum starts to merge in the middle. Scale bar, 1 mm. Bottom, High magnification of micrograph of the
dorsomedial aspect of the striatum from the sections above. There is marked neuronal atrophy with small angulated neurons in
Vec-HD mouse, with relative preservation of neuronal size in CaM-HD mouse. Scale bar, 50 m.
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0.01), and there was a significant interaction between GTPS and
mouse group (F(4,50)  5.032; p  0.01). The activity of guinea
pig liver TGase was measured in each assay in the range from 0.01
to 0.5 mU/ml and resulted in a linear correlation with an R-square
value from 0.95 to 0.99. The activity of TGase in the striatal samples
fell within this linear range for guinea pig liver TGase.
Discussion
Although there have been enormous strides in understanding the
molecular and mechanistic pathways that mediate the progres-
sion of HD, an effective treatment to slow or prevent the disease-
associated physical and mental decline has yet to be discovered. A
number of reports in cultured cells have shown that interfering
peptides can selectively inhibit pathological interactions between
mutant htt and other proteins, and therefore are a potential ther-
apeutic strategy for HD (Nagai et al., 2000; Dudek et al., 2008,
2009). However, only a few studies have been performed to verify
the efficacy of these peptides in vivo (Kazantsev et al., 2002; Tang
et al., 2009). We previously found that plasmid or AAV-
mediated delivery of CaM-fragment significantly attenuated
TGase-modified htt, htt-associated cytotoxicity and intracel-
lular Ca 2 disturbances without interfering with the activity of
other CaM-dependent enzymes in HD cell models (Dudek et al.,
2008, 2009). We now report that expression of the CaM-fragment
in the striatum ameliorated body weight loss, improved motor
performance of R6/2 mice, reduced TGase-modified htt and de-
creased the number and size of nuclear htt-aggregates in the
striatum.
Striatal delivery of CaM-fragment significantly delayed the
onset of movement abnormalities and improved motor function
as measured by analysis of gait, rotarod performance and loco-
motor behavior. It has been reported that gait deficiencies in R6/2
mice became apparent from 8 weeks of age. As visualized in the
footprint analysis, R6/2 mice displayed a significantly shorter
stride length, a staggering movement and a gait that lacked a
uniform step pattern compared with WT littermates (Carter et
al., 1999). Striatal injection of AAV-CaM-fragment conferred
significant improvements in stride length and frequency mea-
surements, and a mild, insignificant increase in paw area at peak
stance in R6/2 mice. Decreased motor function on the rotarod is
the most commonly reported measure among animal models of
HD (Schilling et al., 1999; von Hörsten et al., 2003). Three weeks
after CaM-fragment expression, R6/2 mice started to show sig-
nificantly improved rotarod performance and this beneficial ef-
fect was maintained from 10 weeks of age onward. Although
motor abnormalities such as bradykinesia (abnormally slow
movements) and pronounced hypoactivity were frequently ob-
served in HD animal models (Mangiarini et al., 1996; Keene et al.,
2002), there have been relatively few quantitative studies on
spontaneous locomotor activity of R6/2 mice. In the present ex-
periments using a force-plate actometer, progressive locomotor
deterioration (assessed by number of low mobility bouts and
travel distance) was observed in R6/2 mice injected with control
AAV, whereas delivery of AAV expressing CaM-fragment to R6/2
mice striatum significantly improved their locomotor deficits.
Compared with the TGase inhibitor cystamine, which pro-
longed the life span of R6/2 mice by 12–19% (Dedeoglu et al.,
2002; Karpuj et al., 2002b), there was a nonsignificant increase in
the mean survival time by 10% in the CaM-HD mice. Differ-
ences in other mechanisms of action could possibly account for
the different outcomes. In addition to inhibiting TGase, cysta-
mine increased transcription of neuroprotective genes, increased
glutathione levels, and ameliorated apoptosis (Dedeoglu et al.,
2002; Karpuj et al., 2002b). In contrast, that CaM-fragment de-
creased TGase-modified htt, normalized intracellular calcium re-
lease, and reduced mutant htt-associated cytotoxicity but had no
effect on TGase activity (Dudek et al., 2008, 2009). Second, the
different outcomes could be due to the different brain regions
treated. The CaM-fragment was expressed in the striatum only
while the cystamine-treatment was systemically delivered and
could affect other brain regions that display neuropathology in
HD such as the frontal cortex. Rather than nonspecific inhibition
of TGase by cystamine, disrupting the CaM– htt interaction, as
Table 1. Quantitative analysis of neuropathology
CaM-HD Vec-HD Scr-HD CaM-WT Vec-WT
Percentage of nuclei
containing htt
aggregates (%)
71.7  5.6 85.1  2.1* 89.5  0.8a*
Size of intranuclear htt
aggregates (m 2)
248.4  27.1 378.1  31.5* 391.0  28.2b*
Striatal volume (mm 3) 14.5  0.3 13.8  0.7 13.6  0.3 17.0  0.8 # 17.2  0.4c#
*p  0.05 as compared to CaM-HD (one-way ANOVA, n  5 in each group at 13–14 weeks of age). #p  0.05 as
compared to CaM-HD (one-way ANOVA, n  4 –5 in each group at 14 –20 weeks of age for HD mice, at
27–28 weeks of age for WT mice).
aF(2,12)  6.83.
bF(2,12)  7.38.
cF(4,17)  11.77.
Figure 7. Expression of CaM-fragment in mouse striatum did not significantly affect the
activity CaM kinase II or TGase. a, Mouse striatal homogenates were used to measure CaM
kinase II activity. Two-way ANOVA indicates a significant main effect of EGTA. However, there
was no significant main effect of mouse group. The interaction between EGTA and group was
also not significant. Bonferroni post hoc test indicates no significant differences in CaM kinase II
activity among the various groups in either the presence or absence of EGTA. b, The presence of
the CaM-fragment did not significantly change the levels of TGase activity in either HD or WT
mice. However, a significant elevation of TGase activity in three groups of HD mice was observed
compared with WT mice. When 500 M GTPS was added, there is a dramatic reduction in all
mouse groups. Two-way ANOVA indicates a significant main effect of GTPS and mouse group,
and there is a significant interaction between GTPS and group. Bonferroni post hoc test. *p 
0.01 compared with Vec-WT; #p  0.01 compared with CaM-HD in the absence of GTPS. Each
column represents the mean  SEM (n  5 in each group at 13–14 weeks of age).
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with the CaM-fragment, is a promising new approach for the
treatment HD.
As a result of its expanded N-terminal polyglutamine region,
mutant htt is processed and deposited as a component of insolu-
ble protein aggregates that persist in neuronal nuclei, perikarya,
and processes (DiFiglia et al., 1997). Although some evidence
suggests that htt-associated toxicity is linked to soluble htt and its
protein–protein interactions (Petersen et al., 1999), htt aggre-
gates act as a phenotypic readout that can reflect pathologically
relevant processes such as htt cleavage, misfolding, and seques-
tration (Chopra et al., 2007). A number of compounds which are
neuroprotective in R6/2 mice, such as the TGase inhibitor cysta-
mine (Dedeoglu et al., 2002), the antioxidant coenzyme Q10
(Ferrante et al., 2002) and the energy buffer creatine (Ferrante
et al., 2000), significantly suppress htt aggregates. Our present
results revealed that CaM-fragment significantly reduced
TGase-modified htt in the insoluble fraction, the percentage of
htt-positive nuclei and intranuclear htt-aggregate size in the stri-
atum, which may contribute to the benefits of CaM-fragment.
These findings support the hypothesis that CaM-regulated TGase
modification of htt contributes to the formation and stabilization
of htt-aggregates and may play a role in the pathogenesis of HD.
However, it is difficult to speculate whether there would be an
associated increase in soluble or oligomeric htt in the R6/2 mouse
striatum with CaM-fragment expression. There is evidence that
TGase modifications stabilize proteins (Tucholski et al., 1999), so
inhibiting TGase modifications to htt may increase clearance of
the htt protein.
R6/2 mice developed significant striatal atrophy compared
with WT littermates, a pathological characteristic associated with
the gradual neurodegeneration occurring in the mice. Although
there is no significant difference in striatal volume between
CaM-HD and control-HD mice by light microscopy, we could
not exclude the possibility that expression of CaM-fragment
would reduce the striatal atrophy if a more sensitive technology
(MR scanning) was applied. Moreover, if striatal injections of
AAV were performed at an earlier age, there might be more no-
table beneficial results including increases in survival and striatal
volume.
Similar to increases in TGase protein level and enzymatic ac-
tivity in human HD brain (Karpuj et al., 1999; Lesort et al., 1999),
our results show that TGase activity is elevated in R6/2 mice
compared with WT littermates. Interestingly, striatal delivery of
CaM-fragment did not change the overall activity of TGase in
either R6/2 mice or WT mice. These results are consistent with
our previous studies in cell culture (Dudek et al., 2009), suggest-
ing that CaM-fragment may specifically affect the CaM–mutant
htt interaction and selectively alter TGase-catalyzed modifica-
tions of mutant htt without interfering with the activity of TGase
on other substrate proteins. Furthermore, CaM-fragment ex-
pression did not affect CaM kinase II activity, indicating that
CaM-fragment had no effect on the activity of other CaM-
dependent enzymes. Most importantly, expression of CaM-
fragment in WT mice had no effect on any of the behavioral tests
nor striatal histopathology, suggesting there is minimal, if any,
deleterious effect of long-term expression of CaM-fragment.
A prominent hypothesis on the pathogenesis of HD is that the
aberrant interactions of the extended polyglutamine repeats
(polyQs) of mutant htt, either with other proteins or with each
other result in htt-aggregate formation (Wanker, 2000). Glu-
tamine repeats may function as polar zippers and expansion of
polyQs may increase the affinity of htt for its protein binding
partners (Perutz et al., 1994). The principal proteins that are
known to interact with htt are: htt associated protein 1 (Li et al.,
1995), htt interacting protein (Kalchman et al., 1997), type 1
inositol 1,4,5-trisphosphate receptor (InsP3R1) (Tang et al.,
2003) and calmodulin (Bao et al., 1996; Zainelli et al., 2004). As
revealed by our previous in vitro assay (Dudek et al., 2009), the
neuroprotective effects of CaM-fragment may depend on its abil-
ity to competitively bind to mutant htt thereby disrupting the
CaM–mutant htt interaction. First, this disruption may result in
the CaM and mutant htt no longer in close proximity to each
other, thus the TGase activity in htt modification and aggregate
formation may be reduced. Second, the association between mu-
tant htt and CaM-fragment may prevent the further interaction
of mutant htt with other proteins, such as InsP3R1, an intracel-
lular Ca 2 release channel. Since mutant htt selectively associates
with and activates InsP3R1(Tang et al., 2003), disrupting their
interaction should stabilize neuronal Ca 2 homeostasis. This hy-
pothesis is supported by in vitro experiments that indicated the
CaM-fragment (Dudek et al., 2008) or InsP3R-fragment (Tang et
al., 2009) attenuates mutant htt-associated intracellular Ca 2
disturbances.
Although it will be advantageous to confirm the results from
the current study using a different HD animal model, special care
should be taken to choose a different strain other than R6/2 mice.
Instead of body weight loss, YAC128 mice have significantly
(27%) increased body weight at 12 months of age (Van Raams-
donk et al., 2006, 2007), which in turn can cause bias in most
behavioral tests. Obvious or diffuse nuclear htt accumulation is
not detectable in the striatum or cortices of BAC HD mice even in
18-month-old mice (Gray et al., 2008). Intergenerational insta-
bility and somatic instability of the HD CAG repeat have been
observed in Hdh Q111 knock-in mice in all three background
strains: C57BL/6, FVB/N and 129Sv (Lloret et al., 2006). The
phenotype of N171-82Q mice is more variable than that of R6/2
mice, and therefore a much larger number of mice are necessary
to provide adequate power (Hersch and Ferrante, 2004).
Many therapeutic targets for HD today are based on the
pathogenesis hypotheses, from mitochondrial dysfunction to
transcriptional perturbation to TGase hyperactivity (Beal and
Ferrante, 2004). However, since clinical trials of mechanism-
based therapies for HD have been limited by insufficient statisti-
cal power and insignificant improvement (Handley et al., 2006),
current clinical treatments are symptomatic. The major neuro-
logical symptoms associated with HD include disordered volun-
tary movements: uncoordinated, arrhythmic, and slow fine
motor movements; rigidity; and gait disturbances (Harper,
1991). Our in vivo results demonstrated that viral delivery of
CaM-fragment to the striatum of R6/2 mice significantly im-
proved motor coordination and balance, enhance locomotor ac-
tivity and alleviated gait disturbances, suggesting the possibility
of a better quality of life for HD patients if this new therapeutic
strategy is successfully translated to the clinical trials.
The present studies provide, for the first time, in vivo evidence
that CaM-fragment has significant efficacy in improving the be-
havioral deficits and neuropathological phenotype in the HD an-
imal model. The positive effects of CaM-fragment in R6/2 mice
provide further evidence that CaM-regulated TGase modifica-
tion of htt may contribute to HD pathogenesis. More impor-
tantly, these studies have identified a novel therapeutic strategy
for treating HD patients.
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